



PATENT

I hereby certify that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to the Commissioner for Patents, Washington, DC 20231.

June 8, 2001  
Date

Monica Steinborn  
Monica Steinborn

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Marc W. Retter and Gary R. Fanger  
Application No. : 09/827,271  
Filed : April 4, 2001  
For : COMPOSITIONS AND METHODS FOR THE THERAPY AND  
DIAGNOSIS OF OVARIAN CANCER  
Docket No. : 210121.462C6

Commissioner for Patents  
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached form PTO-1449 (copies of the cited references are enclosed). As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.


#4  
Plunkett  
9/4/01



Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC



Jane E. R. Potter


Registration No. 33,332


JEP:mls

Enclosures:

Postcard  
Form PTO-1449  
Form PTO/SB/21  
Cited References (10)

701 Fifth Avenue, Suite 6300  
Seattle, Washington 98104-7092  
Phone: (206) 622-4900  
Fax: (206) 682-6031

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.462C6		APPLICATION NO. 09/827,271	
 <b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)				APPLICANTS Marc W. Retter and Gary R. Fanger			
				FILING DATE April 4, 2001		GROUP ART UNIT	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	AB						
<b>OTHER PRIOR ART</b> (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AC	Bookman et al., "Biological therapy of ovarian cancer: Current directions," <i>Seminars in Oncology</i> , 25(3):381-396, 1998.					
	AD	Gillespie et al., "Mage, Bage and Gage: Tumour antigen expression in benign and malignant ovarian tissue," <i>British Journal of Cancer</i> , 78(6):816-821, September, 1998.					
	AE	Heller et al., "Discovery and analysis of inflammatory disease-related genes using cDNA microarrays," <i>Proc. Natl. Acad. Sci. USA</i> 94:2150-2155, March, 1997.					
	AF	Ishikawa et al., "Prediction of the coding sequence of unidentified human genes. The complete sequence of 100 new cDNA clones from brain which can code for large proteins in vitro," <i>DNA Res.</i> , 5:169-176, 1998.					
	AG	Jin et al., "Human T cell leukemia virus type I oncoprotein tax targets the human mitotic checkpoint protein MAD1," <i>Cell</i> 93:81-91, April 3, 1998.					
	AH	Köhler et al., "Immunotherapy of Ovarian Carcinoma with the Monoclonal Anti-Idiotypic Antibody ACA125 - Results of the Phase LB Study," <i>Gebrutshilfe und Fraenheilkunde</i> , 58(4):180-186, April 1998 + (English Abstract).					
	AI	Ma et al., "Use of encapsulated single chain antibodies for induction of anti-idiotypic humoral and cellular immune responses," <i>Journal of Pharmaceutical Sciences</i> , 87(11):1375-1378, November, 1998.					
	AJ	Parker et al., "Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains," <i>The Journal of Immunology</i> 152(1):163-175, January 1, 1994.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449  
(REV.7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
210121.462C6APPLICATION NO.  
09/827,271**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

## APPLICANTS

Marc W. Retter and Gary R. Fanger

FILING DATE  
April 4, 2001

GROUP ART UNIT

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
BA						

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
BB							

**OTHER PRIOR ART** (Including Author, Title, Date, Pertinent Pages, Etc.)

BC	Peoples et al., "Ovarian cancer-associated lymphocyte recognition of folate binding protein peptides," <i>Annals of Surgical Oncology</i> , 5(8):743-750, December, 1998.
BD	Schena et al., "Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes," <i>Proc. Natl. Acad. Sci.</i> , 93:10614-10619, October, 1996.
BE	
BF	
BG	
BH	
BI	
BJ	

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).